Literature DB >> 29018276

IBD: Step-up vs top-down therapy for Crohn's disease: medicine vs surgery.

Bo Shen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29018276     DOI： 10.1038/nrgastro.2017.139

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Clinical Practice Guideline for the Surgical Management of Crohn's Disease.

Authors:  Scott Strong; Scott R Steele; Marylise Boutrous; Liliana Bordineau; Jonathan Chun; David B Stewart; Jon Vogel; Janice F Rafferty
Journal:  Dis Colon Rectum       Date:  2015-11       Impact factor: 4.585

2.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

Authors:  Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes
Journal:  Lancet       Date:  2008-02-23       Impact factor: 79.321

Review 3.  Treatment algorithms in Crohn's - up, down or something else?

Authors:  Ophélie Antunes; Jérôme Filippi; Xavier Hébuterne; Laurent Peyrin-Biroulet
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-05-17       Impact factor: 3.043

4.  Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.

Authors:  Cyriel Y Ponsioen; E Joline de Groof; Emma J Eshuis; Tjibbe J Gardenbroek; Patrick M M Bossuyt; Ailsa Hart; Janindra Warusavitarne; Christianne J Buskens; Ad A van Bodegraven; Menno A Brink; Esther C J Consten; Bart A van Wagensveld; Marno C M Rijk; Rogier M P H Crolla; Casper G Noomen; Alexander P J Houdijk; Rosalie C Mallant; Maarten Boom; Willem A Marsman; Hein B Stockmann; Bregje Mol; A Jeroen de Groof; Pieter C Stokkers; Geert R D'Haens; Willem A Bemelman
Journal:  Lancet Gastroenterol Hepatol       Date:  2017-08-31

Review 5.  Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.

Authors:  E J Mao; G S Hazlewood; G G Kaplan; L Peyrin-Biroulet; A N Ananthakrishnan
Journal:  Aliment Pharmacol Ther       Date:  2016-11-10       Impact factor: 8.171

Review 6.  The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.

Authors:  Gert Van Assche; James D Lewis; Gary R Lichtenstein; Edward V Loftus; Qin Ouyang; Julian Panes; Corey A Siegel; William J Sandborn; Simon P L Travis; Jean-Frederic Colombel
Journal:  Am J Gastroenterol       Date:  2011-08-16       Impact factor: 10.864

7.  Long-term evolution of disease behavior of Crohn's disease.

Authors:  Jacques Cosnes; Stéphane Cattan; Antoine Blain; Laurent Beaugerie; Franck Carbonnel; Rolland Parc; Jean-Pierre Gendre
Journal:  Inflamm Bowel Dis       Date:  2002-07       Impact factor: 5.325

8.  Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients.

Authors:  Kweku A Appau; Victor W Fazio; Bo Shen; James M Church; Bret Lashner; Feza Remzi; Aaron Brzezinski; Scott A Strong; Jeffrey Hammel; Ravi P Kiran
Journal:  J Gastrointest Surg       Date:  2008-08-15       Impact factor: 3.452

9.  Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial.

Authors:  Reena Khanna; Brian Bressler; Barrett G Levesque; Guangyong Zou; Larry W Stitt; Gordon R Greenberg; Remo Panaccione; Alain Bitton; Pierre Paré; Séverine Vermeire; Geert D'Haens; Donald MacIntosh; William J Sandborn; Allan Donner; Margaret K Vandervoort; Joan C Morris; Brian G Feagan
Journal:  Lancet       Date:  2015-09-03       Impact factor: 79.321

Review 10.  Anti-Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper.

Authors:  Stefan D Holubar; Jennifer Holder-Murray; Mark Flasar; Mark Lazarev
Journal:  Inflamm Bowel Dis       Date:  2015-11       Impact factor: 5.325
  10 in total
  1 in total

1.  Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial.

Authors:  Xiuxiu Hao; Tienan Feng; Yang Yang; Yuan Shi; Ran Jing; Sailiang Liu; Yang Luo; Yuqi Qiao; Ming Zhong; Minhao Yu
Journal:  BMJ Open       Date:  2020-11-16       Impact factor: 2.692
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.